Michael Mutolo Email

Senior Scientist, Quality Control . EVOQ Therapeutics

Current Roles

Employees:
11
Revenue:
$1.7M
About
EVOQ Therapeutics is developing immunotherapies to improve the lives of individuals fighting autoimmune diseases.\n\nThere are more than 100 chronic autoimmune diseases - many severely debilitating, and some life-threatening. According to the National Institutes of Health, up to 23.5 million Americans (over 7% of the population) suffer from autoimmune disease, and the prevalence is rising.\n\nAutoimmune disease occurs when the body’s central immune tolerance system fails - resulting in T and B cell-mediated destruction of self-tissues. This immune system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis and Rheumatoid Arthritis.\n\nEVOQ’s technology unleashes and restores the body’s natural immune tolerance pathways.
EVOQ Therapeutics Address

Ann Arbor, MI
United States
EVOQ Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.